The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector
Open accessAbstract
Adeno-associated virus (AAV) has shown great promise as a gene therapy vector in multiple aspects of preclinical and clinical applications. Many developments including new serotypes as well as self-complementary vectors are now entering the clinic. With these ongoing vector developments, continued effort has been focused on scalable manufacturing processes that can efficiently generate high-titer, highly pure, and potent quantities of rAAV vectors. Utilizing the relatively simple and efficient transfection system of HEK293 cells as a starting point, we have successfully adapted an adherent HEK293 cell line from a qualified clinical master cell bank to grow in animal component-free suspension conditions in shaker flasks and WAVE bioreactors that allows for rapid and scalable rAAV production. Using the triple transfection method, the suspension HEK293 cell line generates greater than 1 × 10(5) vector genome containing particles (vg)/cell or greater than 1 × 10(14) vg/l of cell culture when harvested 48 hours post-transfection. To achieve these yields, a number of variables were optimized such as selection of a compatible serum-free suspension media that supports both growth and transfection, selection of a transfection reagent, transfection conditions and cell density. A universal purification strategy, based on ion exchange chromatography methods, was also developed that results in high-purity vector preps of AAV serotypes 1-6, 8, 9 and various chimeric capsids tested. This user-friendly process can be completed within 1 week, results in high full to empty particle ratios (>90% full particles), provides postpurification yields (>1 × 10(13) vg/l) and purity suitable for clinical applications and is universal with respect to all serotypes and chimeric particles. To date, this scalable manufacturing technology has been utilized to manufacture GMP phase 1 clinical AAV vectors for retinal neovascularization (AAV2), Hemophilia B (scAAV8), giant axonal neuropathy (scAAV9), and retinitis pigmentosa (AAV2), which have been administered into patients. In addition, we report a minimum of a fivefold increase in overall vector production by implementing a perfusion method that entails harvesting rAAV from the culture media at numerous time-points post-transfection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Self-citationZolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Self-citationAdenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004
Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Self-citationMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
Self-citationNovel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2745 · Cited by 696
Production and characterization of adeno-associated viral vectors
Grieger, J. C., Choi, V. W., & Samulski, R. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.207 · Cited by 581
Self-citationProduction and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 565
Adeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500
Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457
A viral assembly factor promotes AAV2 capsid formation in the nucleolus
Sonntag, F., Schmidt, K., & Kleinschmidt, J. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001673107 · Cited by 392
Thomas, M., Lu, J. J., Ge, Q., Zhang, C., Chen, J., & Klibanov, A. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502067102 · Cited by 366
Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale
Lock, M., Alvira, M., Vandenberghe, L. H., Samanta, A., Toelen, J., Debyser, Z., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.055 · Cited by 334
Herpes Simplex Virus Types 1 and 2 Completely Help Adenovirus-Associated Virus Replication
Buller, R. M. L., Janik, J. E., Sebring, E. D., & Rose, J. A. (1981) · Journal of Virology · doi:10.1128/jvi.40.1.241-247.1981 · Cited by 332
Clinical gene therapy using recombinant adeno-associated virus vectors
Mueller, C., & Flotte, T. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.68 · Cited by 313
Scalable Purification of Adeno-Associated Virus Type 2, 4, or 5 Using Ion-Exchange Chromatography
Kaludov, N., Handelman, B., & Chiorini, J. A. (2002) · Human Gene Therapy · doi:10.1089/104303402320139014 · Cited by 167
Conway, J. E., Rhys, C. A., Zolotukhin, I., Zolotukhin, S., Muzyczka, N., Hayward, G. S., & Byrne, B. J. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300937 · Cited by 158
Vandenberghe, L. H., Xiao, R., Lock, M., Lin, J., Korn, M., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.107 · Cited by 151
Successful Production of Pseudotyped rAAV Vectors Using a Modified Baculovirus Expression System
Kohlbrenner, E., Aslanidi, G., Nash, K. R., Shklyaev, S., Campbell‐Thompson, M., Byrne, B. J., Snyder, R. O., Muzyczka, N., Warrington, K. H., & Zolotukhin, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.018 · Cited by 142
Davidoff, A. M., Ng, C. Y., Sleep, S., Gray, J. T., Azam, S. A., Zhao, Y., McIntosh, J., Karimipoor, M., & Nathwani, A. C. (2004) · Journal of Virological Methods · doi:10.1016/j.jviromet.2004.07.001 · Cited by 124
Scalable Generation of High-Titer Recombinant Adeno-Associated Virus Type 5 in Insect Cells
Urabe, M., Nakakura, T., Xin, K.-Q., Obara, Y., Mizukami, H., Kume, A., Kotin, R. M., & Ozawa, K. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.1874-1885.2006 · Cited by 117
Thomas, D. L., Wang, L., Niamke, J., Liu, J., Kang, W., Scotti, M. M., Ye, G., Veres, G., & Knop, D. R. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.004 · Cited by 106
Aslanidi, G., Lamb, K. E., & Zolotukhin, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810614106 · Cited by 95
Durocher, Y., Pham, P. L., St‐Laurent, G., Jacob, D., Cass, B., Chahal, P. S., Lau, C. J., Nalbantoglu, J. N., & Kamen, A. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2007.03.014 · Cited by 94
Chadeuf, G., Favre, D., Tessier, J., Provost, N., Nony, P., Kleinschmidt, J., Moullier, P., & Salvetti, A. (2000) · The Journal of Gene Medicine · doi:10.1002/1521-2254(200007/08)2:4<260::aid-jgm111>3.0.co;2-8 · Cited by 88
Critical assessment of current adeno-associated viral vector production and quantification methods
Aucoin, M. G., Perrier, M., & Kamen, A. (2007) · Biotechnology Advances · doi:10.1016/j.biotechadv.2007.09.001 · Cited by 65
Hildinger, M., Baldi, L., Stettler, M., & Wurm, F. M. (2007) · Biotechnology Letters · doi:10.1007/s10529-007-9441-3 · Cited by 57
Negrete, A., Yang, L. C., Mendez, A. F., Levy, J. R., & Kotin, R. M. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1092 · Cited by 56
An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes
Kang, W., Wang, L., Harrell, H., Liu, J., Thomas, D., Mayfield, T. L., Scotti, M. M., Ye, G. J., Veres, G., & Knop, D. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.158 · Cited by 55
Scalable production of adeno‐associated virus type 2 vectors via suspension transfection
Park, J. Y., Lim, B., Lee, K., Kim, Y. K., & Jo, E. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20776 · Cited by 53
Toward exascale production of recombinant adeno-associated virus for gene transfer applications
Cecchini, S., Negrete, A., & Kotin, R. M. (2008) · Gene Therapy · doi:10.1038/gt.2008.61 · Cited by 46
Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids
Booth, M. J., Mistry, A., Li, X., Thrasher, A. J., & Coffin, R. S. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302226 · Cited by 44
Large-Scale Production of Recombinant Adeno-Associated Viral Vectors
Negrete, A., & Kotin, R. M. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-237-3_5 · Cited by 18
(2003) · Molecular Therapy · doi:10.1016/s1525-0016(16)40477-6 · Cited by 5
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationSystemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Self-citation
Metadata
- Authors
- Grieger, J. C., Soltys, S. M., & Samulski, R. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 24
- Issue
- 2
- Pages
- 287-297
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2223143741
- Cited by
- 325
- References
- 35
- FWCI
- 11.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.